• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$0.40 $0.01 (1.28%)

Quote as of

NEMASKA EXPLORATION INC.

TSXV:NMX

Jump to this page for:

Related Resources

Transition Therapeutics Announces ELND005 Presentations at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies

5/14/2012 by StockHouse

Transition Therapeutics Announces ELND005 Presentations at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies

5/14/2012 by StockWatch

Transition Therapeutics Announces ELND005 Presentations at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies

5/14/2012 by GlobeNewswire

Transition Therapeutics reports Q3 EPS (C11c), one estimate (25c)

5/8/2012 by Theflyonthewall.com

Transition Therapeutics Announces Third Quarter Fiscal 2012 Financial Results

5/8/2012 by StockWatch

Transition Therapeutics Announces Third Quarter Fiscal 2012 Financial Results

5/8/2012 by GlobeNewswire

Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2012 Financial Results on Tuesday, May 8th, at 4:30 P.M. EDT

5/4/2012 by StockHouse

Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2012 Financial Results on T

5/4/2012 by NASDAQ

eResearch Issues Perspective on Nemaska Lithium Inc. (VAN:NMX)

5/2/2012 by AccessWire

Transition Therapeutics Announces ELND-005 Presentations at the American Academy of Neurology Meeting

4/26/2012 by StockHouse

Transition Therapeutics Announces ELND-005 Presentations at the American Academy of Neurology Meeting

4/26/2012 by StockWatch

Transition Therapeutics Announces ELND-005 Presentations at the American Academy of Neurology Meeting

4/26/2012 by GlobeNewswire

eResearch Issues Perspective on Nemaska Lithium Inc. (VAN:NMX)

3/22/2012 by AccessWire

Transition Therapeutics to Present at the Cowen & Company 32nd Annual Health Care Conference

3/1/2012 by GlobeNewswire

Transition Therapeutics, Inc. (TTHI) Reports Q2 Loss of $0.15, Had No Revenue

2/9/2012 by StreetInsider.com

Transition Therapeutics loses $3.79-million in Q2 2012

2/9/2012 by StockWatch

Transition Therapeutics reports Q2 EPS (15c) vs. consensus (23c)

2/9/2012 by Theflyonthewall.com

Transition Therapeutics Announces Second Quarter Fiscal 2012 Financial Results

2/9/2012 by GlobeNewswire

Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2012 Financial Results on Thursday, February 9th, at 4:30 P.M. EST

2/7/2012 by StockHouse

Transition Therapeutics to hold Q2 results call Feb. 9

2/7/2012 by StockWatch

Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2012 Financial Results on Thursday, February 9th, at 4:30 P.M. EST

2/7/2012 by GlobeNewswire

Transition Therapeutics starts TT-401 study doses

12/12/2011 by StockWatch

Transition Therapeutics (TTHI) Promotes Nicole Rusaw-George to CFO

12/12/2011 by StreetInsider.com

Transition Therapeutics (TTHI) Doses First Patient in TT-401 Phase 1

12/12/2011 by StreetInsider.com

Transition Therapeutics announces initiation of TT-401 Phase l clinical study

12/12/2011 by Theflyonthewall.com

Transition Therapeutics names Rusaw-George as CFO

12/12/2011 by StockWatch

Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401

12/12/2011 by StockWatch

Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401

12/12/2011 by GlobeNewswire

Transition Therapeutics announces departure of its president and CFO

12/11/2011 by Theflyonthewall.com

Transition Therapeutics president, CFO Farah leaves

12/9/2011 by StockWatch

Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer

12/9/2011 by StockWatch

Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer

12/9/2011 by GlobeNewswire

Elan, Lonza in Supply Deal - Analyst Blog

12/5/2011 by Zacks Investment Research

Elan, Lonza in Supply Deal

12/5/2011 by Zacks Equity Research Analyst Blog

Elan, Lonza in Supply Deal - Analyst Blog

12/5/2011 by NASDAQ

Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results

12/1/2011 by StockHouse

5 Stocks With Huge Insider Buying

12/1/2011 by TheStreet.com

Transition Therapeutics to hold Q1 call on Dec. 1

11/29/2011 by StockWatch

Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST

11/29/2011 by StockHouse

Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST

11/29/2011 by StockWatch
See More Articles...